Johns Hopkins ABX Guide
Maribavir
INDICATIONS
FDA
FDA
- Treatment of post-transplant CMV infection/disease that is refractory to treatment (with or without genotypic resistance) with ganciclovir, valganciclovir, cidofovir, or foscarnet in adults and pediatric patients (≥12 years of age and weighing at least 35 kg)
- For any patient to be started on maribavir, use of the Takeda Livtencity PATIENT START FORM is required.
There's more to see -- the rest of this topic is available only to subscribers.
Last updated: May 11, 2022
Citation
Dzintars, Kathryn. "Maribavir." Johns Hopkins ABX Guide, The Johns Hopkins University, 2022. Pediatrics Central, peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540764/all/Maribavir.
Dzintars K. Maribavir. Johns Hopkins ABX Guide. The Johns Hopkins University; 2022. https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540764/all/Maribavir. Accessed November 17, 2024.
Dzintars, K. (2022). Maribavir. In Johns Hopkins ABX Guide. The Johns Hopkins University. https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540764/all/Maribavir
Dzintars K. Maribavir [Internet]. In: Johns Hopkins ABX Guide. The Johns Hopkins University; 2022. [cited 2024 November 17]. Available from: https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540764/all/Maribavir.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Maribavir
ID - 540764
A1 - Dzintars,Kathryn, Pharm.D., BCPS
Y1 - 2022/05/11/
BT - Johns Hopkins ABX Guide
UR - https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540764/all/Maribavir
PB - The Johns Hopkins University
DB - Pediatrics Central
DP - Unbound Medicine
ER -
